Caitong International Asset Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Caitong International Asset Management’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36	Buy	+23	New	+$48	﹤0.01%	2405

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Caitong International Asset Management's ACXP Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Acurx Pharmaceuticals (ACXP) in Q2 2026: 23 shares worth $36. The stake represents ﹤0.01% of the portfolio and ranks #2405 among its holdings.

19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

Caitong International Asset Management held 23 shares of Acurx Pharmaceuticals worth $36 as of Q2 2026.
Acurx Pharmaceuticals was a new Caitong International Asset Management position in Q2 2026.
Acurx Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2405 holding.
19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.